Gilead Sciences (GILD) Set to Announce Quarterly Earnings on Monday

Gilead Sciences (NASDAQ:GILD) is scheduled to be announcing its earnings results after the market closes on Monday, February 5th. Analysts expect the company to announce earnings of $1.71 per share for the quarter.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the previous year, the firm earned $2.75 earnings per share. The firm’s revenue for the quarter was down 13.2% compared to the same quarter last year. On average, analysts expect Gilead Sciences to post $9 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Shares of Gilead Sciences (NASDAQ:GILD) opened at $85.46 on Monday. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $86.27. The firm has a market cap of $111,600.00, a price-to-earnings ratio of 9.72, a price-to-earnings-growth ratio of -1.79 and a beta of 1.13.

In related news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the sale, the executive vice president now owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold 591,666 shares of company stock valued at $44,466,567 in the last ninety days. Corporate insiders own 1.30% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Rowland & Co. Investment Counsel ADV acquired a new stake in Gilead Sciences in the second quarter worth about $153,000. Kingfisher Capital LLC acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $212,000. Keel Point LLC lifted its holdings in Gilead Sciences by 0.4% in the 2nd quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 12 shares during the last quarter. Colony Group LLC acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $229,000. Finally, Linscomb & Williams Inc. lifted its holdings in Gilead Sciences by 10.1% in the 2nd quarter. Linscomb & Williams Inc. now owns 5,806 shares of the biopharmaceutical company’s stock valued at $411,000 after acquiring an additional 531 shares during the last quarter. 76.06% of the stock is owned by institutional investors and hedge funds.

GILD has been the subject of several analyst reports. BMO Capital Markets reissued a “hold” rating and set a $82.00 price target on shares of Gilead Sciences in a report on Friday, October 20th. JPMorgan Chase & Co. set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, October 25th. Morgan Stanley reissued an “equal weight” rating and set a $83.00 price target (up previously from $77.00) on shares of Gilead Sciences in a report on Friday, October 6th. Bank of America reduced their price target on shares of Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating for the company in a report on Wednesday, October 4th. Finally, Vetr downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target for the company. in a report on Wednesday, January 17th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eighteen have assigned a buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and a consensus target price of $85.53.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/01/29/gilead-sciences-gild-set-to-announce-quarterly-earnings-on-monday.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Earnings History for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply